Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ELANE | P08246 | 13/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.36 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.36 |
| ▸ | MAPT | P10636 | 1/20 | 0.35 |
| ▸ | HTT | P42858 | 1/20 | 0.35 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.35 |
| ▸ | POLB | P06746 | 1/20 | 0.33 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1109013 | 0.75 | NPSR1 (0.42) | LMNATDP1MAPTHTTNPSR1 | |
| SCHEMBL15218658 | 0.70 | ELANE (0.45) | ELANEMAPT | |
| SCHEMBL33145 | 0.69 | ALDH1A1 (0.43) | LMNATDP1MAPTHTTNPSR1 | |
| SCHEMBL28589686 | 0.69 | ELANE (0.37) | ELANENPSR1CYP1A2 | |
| SCHEMBL12739634 | 0.68 | KMT2A (0.48) | ELANETDP1MAPTHTTPOLB | |
| SCHEMBL18791241 | 0.67 | ELANE (0.39) | ELANEMAPT | |
| SCHEMBL9371729 | 0.67 | LMNA (0.38) | LMNATDP1MAPTHTTNPSR1 | |
| SCHEMBL9256983 | 0.67 | GAA (0.35) | LMNATDP1MAPTHTTNPSR1 | |
| SCHEMBL18785781 | 0.66 | ELANE (0.42) | ELANEMAPT | |
| SCHEMBL14804852 | 0.65 | GAA (0.41) | LMNATDP1MAPTHTTNPSR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210338834-A1 | DEGRADABLE HYALURONIC ACID HYDROGELS | ASCENDIS PHARMA A/S (DK) | 2021-11-04 | — | — | US | disclosed |
| US-20210330798-A1 | TREATMENT OF INFECTIONS | ASCENDIS PHARMA A/S (DK) | 2021-10-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210338834-A1 | DEGRADABLE HYALURONIC ACID HYDROGELS | CD44, HPSE, MMP13 | ELANE 686/4885LMNA 2801/4885TDP1 1372/4885 |
| US-20210330798-A1 | TREATMENT OF INFECTIONS | H1-10, PM20D2, ELANE | ELANE 3/4885LMNA 2251/4885TDP1 3622/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.